Teleflex Incorporated (NYSE:TFX) – Equities research analysts at KeyCorp lifted their Q3 2017 EPS estimates for Teleflex in a research report issued to clients and investors on Thursday. KeyCorp analyst M. Mishan now expects that the medical technology company will earn $2.03 per share for the quarter, up from their previous estimate of $2.01. KeyCorp also issued estimates for Teleflex’s FY2017 earnings at $8.30 EPS and FY2018 earnings at $9.55 EPS.

TFX has been the subject of several other research reports. Barclays PLC reissued a “buy” rating on shares of Teleflex in a research note on Monday, June 26th. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $228.00 target price for the company in a research note on Friday, June 23rd. Deutsche Bank AG boosted their target price on Teleflex from $213.00 to $220.00 and gave the stock a “buy” rating in a research note on Monday, May 8th. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a research note on Friday. Finally, Jefferies Group LLC reissued a “buy” rating and set a $230.00 target price on shares of Teleflex in a research note on Thursday. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Teleflex has an average rating of “Buy” and a consensus price target of $221.17.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/brokers-issue-forecasts-for-teleflex-incorporateds-q3-2017-earnings-tfx.html.

Shares of Teleflex (NYSE:TFX) opened at 214.26 on Monday. The firm’s 50-day moving average is $207.61 and its 200-day moving average is $195.00. Teleflex has a one year low of $136.53 and a one year high of $217.97. The company has a market cap of $9.64 billion, a price-to-earnings ratio of 44.47 and a beta of 1.05.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The firm had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. During the same quarter in the prior year, the firm earned $1.89 EPS. The company’s revenue was up 11.6% on a year-over-year basis.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Friday, August 11th. Teleflex’s dividend payout ratio (DPR) is currently 26.00%.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $199.93, for a total transaction of $39,986.00. Following the sale, the director now directly owns 8,080 shares in the company, valued at $1,615,434.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Stuart A. Randle sold 2,500 shares of the business’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $205.67, for a total value of $514,175.00. Following the sale, the director now owns 7,532 shares in the company, valued at $1,549,106.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,546 shares of company stock worth $2,079,856. Company insiders own 2.39% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Asset Planning Services Ltd. purchased a new stake in Teleflex during the first quarter valued at $116,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Teleflex during the first quarter valued at $155,000. OLD Mutual Customised Solutions Proprietary Ltd. boosted its stake in Teleflex by 200.0% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Teleflex during the second quarter valued at $200,000. Finally, Harvey Capital Management Inc. purchased a new stake in Teleflex during the second quarter valued at $207,000. Institutional investors own 92.95% of the company’s stock.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.